As such, we propose USP7 inhibitors as a new class of small molecule immune modulators specifically targeting cancer‐associated fibroblasts with therapeutic potential in solid tumours that are unresponsive to existing immune oncology treatments. This evidence concerns the gene USP7 and cancer.